5-acetoxy-4,6-di-tert-butylbenzofuran | 157360-69-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 5-acetoxy-4,6-di-tert-butylbenzofuran
• 英文别名: (4,6-ditert-butyl-1-benzofuran-5-yl) acetate
• CAS: 157360-69-5
• 化学式: C₁₈H₂₄O₃
• 分子量: 288.387
• InChiKey: ATFPLQAPABRYMU-UHFFFAOYSA-N

物化性质

• 沸点：
  355.6±42.0 °C(Predicted)
• 密度：
  1.039±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-acetoxy-4,6-di-tert-butylbenzofuran 在 盐酸 作用下， 以 四氢呋喃 、 正己烷 、 水 、 乙酸乙酯 为溶剂， 以98%的产率得到4,6-di-tert-butyl-5-benzofuranol
  参考文献：
  名称：

  4,6-Di-t-butyl-dihydrobenzofuran-5-ol and its derivatives

  摘要：

  通式表示的化合物以及其合成的中间体：##STR1##其中R.sup.1是氢原子或酰基；R.sup.2是较低的烷基；R.sup.3是氢原子或较低的烷基；R.sup.4、R.sup.5和R.sup.6，可以相同也可以不同，是氢原子或可选择取代的烷基、烯基、炔基或芳基；当R.sup.2和R.sup.4一起时，可以形成一个5-成员环；当R.sup.5和R.sup.6一起时，可以形成一个环烷基或一个杂环基，其中环烷基的环上至少有一个甲基被氧原子、硫原子或烷基取代的氮原子取代，前提是如果由R.sup.2和R.sup.4一起形成的环是苯并呋喃环，则R.sup.6不存在。通式（I）表示的化合物具有高度选择性的抗氧化活性，并且可用作治疗缺血性疾病，如动脉粥样硬化和心肌梗死的药物。

  公开号：

  US05574178A1
• 作为产物：
  描述：

  2,6-二叔丁基-4-甲氧基苯酚 在 sodium periodate 、 四氧化锇 、 碘代三甲硅烷 、 硫酸 、 potassium carbonate 、 N,N-二甲基苯胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 为溶剂， 反应 165.0h， 生成 5-acetoxy-4,6-di-tert-butylbenzofuran
  参考文献：
  名称：

  Design and Synthesis of 4,6-Di-tert-butyl-2,3-dihydro-5-benzofuranols as a Novel Series of Antiatherogenic Antioxidants

  摘要：

  Antioxidants have been considered as potential antiatherogenic agents by inhibiting oxidation of low-density lipoprotein (LDL), albeit vitamin E, a natural antioxidant, has failed to show reduction on atherosclerosis in clinical trials. We have rationally designed and synthesized a novel series of antioxidants, 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols, to overcome the clinical limitation of vitamin E. In vitro, the compounds showed a potent inhibitory effect on lipid peroxidation detected as 2-methyl-6-(p-methoxyphenyl)-3,7-dihydroimidazo[1,2-a]pyrazin3-one (MCLA)-dependent chemiluminescence in linoleic acid autoxidation. They also inhibited the LDL oxidation induced by Cu2+, and the inhibition is more potent than that of vitamin E and probucol. In vivo, 4,6-di-tert-butyl-2,3-dihydro-2,2-dipentyl-5-benzofuranoI (BO-653, 1f), an optimal compound, showed the highest concentration in plasma and LDL fraction in Watanabe heritable hyperlipidemic rabbits, due to its high affinity to LDL. The isolated LDL samples from the If-treated rabbits showed potent resistibility to LDL oxidation. Compound If has been taken into clinical trials.

  DOI：

  10.1021/jm030062a

文献信息

• 4,6-Di-t-butyl-dihydrobenzofuran-5-ol and its derivatives
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US05574178A1

  公开（公告）日：1996-11-12

  Compounds represented by the general formula as well as intermediates for the synthesis of thereof: ##STR1## where R.sup.1 is a hydrogen atom or an acyl group; R.sup.2 is a lower alkyl group; R.sup.3 is a hydrogen atom or a lower alkyl group; R.sup.4, R.sup.5 and R.sup.6, which may be the same or different, are a hydrogen atom or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; R.sup.2 and R.sup.4, when taken together, may form a 5-membered ring; R.sup.5 and R.sup.6, when taken together, may form a cycloalkyl group or a heterocyclic group in which at least one methylene on the ring of a cycloalkyl group is substituted by an oxygen atom, a sulfur atom or an alkyl-substituted nitrogen atom, provided that R.sup.6 is not present if the ring formed by R.sup.2 and R.sup.4 taken together is a benzofuran ring. The compounds represented by the general formula (I) have a highly selective anti-oxidative activity and are useful as therapeutics of ischemic diseases such as arteriosclerosis and myocardial infarction.

  通式表示的化合物以及其合成的中间体：##STR1##其中R.sup.1是氢原子或酰基；R.sup.2是较低的烷基；R.sup.3是氢原子或较低的烷基；R.sup.4、R.sup.5和R.sup.6，可以相同也可以不同，是氢原子或可选择取代的烷基、烯基、炔基或芳基；当R.sup.2和R.sup.4一起时，可以形成一个5-成员环；当R.sup.5和R.sup.6一起时，可以形成一个环烷基或一个杂环基，其中环烷基的环上至少有一个甲基被氧原子、硫原子或烷基取代的氮原子取代，前提是如果由R.sup.2和R.sup.4一起形成的环是苯并呋喃环，则R.sup.6不存在。通式（I）表示的化合物具有高度选择性的抗氧化活性，并且可用作治疗缺血性疾病，如动脉粥样硬化和心肌梗死的药物。
• 4-alkoxy-2, 6-di-t-butylphenol derivatives
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US05606089A1

  公开（公告）日：1997-02-25

  Compounds represented by the general formula (I), as well as intermediates for the synthesis of thereof: ##STR1## where R.sup.1 is a hydrogen atom or an acyl group; R.sup.2 is a lower alkyl group; R.sup.3 is a hydrogen atom or a lower alkyl group; R.sup.4, R.sup.5 and R.sup.6, which may be the same or different, are a hydrogen atom or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; R.sup.2 and R.sup.4, when taken together, may form a 5-membered ring; R.sup.5 and R.sup.6, when taken together, may form a cycloalkyl group or a heterocyclic group in which at least one methylene on the ring of a cycloalkyl group is substituted by an oxygen atom, a sulfur atom or an alkyl-substituted nitrogen atom, provided that R.sup.6 is not present if the ring formed by R.sup.2 and R.sup.4 taken together is a benzofuran ring. The compounds represented by the general formula (I) have a highly selective anti-oxidative activity and are useful as therapeutics of ischemic diseases such as arteriosclerosis and myocardial infarction.

  通式（I）所代表的化合物以及其合成中间体： 其中，R.sup.1是氢原子或酰基基团；R.sup.2是较低的烷基基团；R.sup.3是氢原子或较低的烷基基团；R.sup.4，R.sup.5和R.sup.6，可以相同也可以不同，是氢原子或可选取代的烷基，烯基，炔基或芳基基团；当R.sup.2和R.sup.4结合在一起时，可以形成一个5元环；当R.sup.5和R.sup.6结合在一起时，可以形成一个环烷基或杂环基，在环烷基上至少有一个亚甲基被氧原子，硫原子或烷基取代的氮原子所取代，但是当R.sup.2和R.sup.4结合在一起形成苯并呋喃环时，R.sup.6不存在。通式（I）所代表的化合物具有高度选择性的抗氧化活性，可用作缺血性疾病如动脉硬化和心肌梗塞的治疗剂。
• INTIMAL THICKENING INHIBITOR
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP0868913A1

  公开（公告）日：1998-10-07

  An intimal thickening inhibitory agent comprising, as an active ingredient, a compound represented by formula (1): wherein X represents an oxygen atom or a group of formula (2): wherein n represents an integer of from 0 to 2, R1 represents a hydrogen atom or an acyl group; R2 represents a hydrogen atom, a lower alkyl group or a lower alkenyl group; R3 represents a lower alkyl group; and R4, R5, and R6, which may be the same or different, each represent a hydrogen atom or a substituted or unsubstituted alkyl group; or R3 and R4 may be taken together to form a 5-membered ring; or R5 and R6 may be taken together to form a cycloalkyl group; provided that R6 is nil when R3 and R4 are taken together to form benzofuran or benzo[b]thiophene.

  一种内膜增厚抑制剂，其活性成分包括由式（1）代表的化合物： 其中 X 代表氧原子或式（2）的基团： 其中 n 代表 0 至 2 的整数、 R1 代表氢原子或酰基； R2 代表氢原子、低级烷基或低级烯基； R3 代表低级烷基； R4、R5 和 R6 可以相同或不同，各自代表氢原子或取代或未取代的烷基；或 R3 和 R4 组合在一起形成五元环；或 R5 和 R6 组合在一起形成环烷基；但当 R3 和 R4 组合在一起形成苯并呋喃或苯并[b]噻吩时，R6 为零。
• REMEDIES FOR RENAL DISEASES AND ORGAN-PRESERVING AGENTS
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP0950405A1

  公开（公告）日：1999-10-20

  Herein disclosed are therapeutic agents for renal diseases and organ preservatives containing a compound represented by the general formula (1): wherein X represents an oxygen atom or a group represented by the general formula (2): where n represents an integer from 0 to 2, R1 represents a hydrogen atom or an acyl group, R2 represents a hydrogen atom, a lower alkyl group or a lower alkenyl group, R3 represents a lower alkyl group, R4, R5 and R6, which may be the same or different, each represents a hydrogen atom or an optionally substituted alkyl group, and R6 further represents a formyl, carboxyl, lower alkoxycarbonyl or optionally substituted carbamoyl group, or R3 and R4 may be taken together to form a five-membered ring, or R5 and R6 may be taken together to form a cycloalkyl group, provided that when the five-membered ring formed by R3 and R4 and the benzene ring form benzofuran or benzo[b]thiophene, R6 is absent.

  这里公开的是含有通式（1）所代表的化合物的肾病治疗剂和器官防腐剂： 其中 X 代表氧原子或通式（2）所代表的基团： 其中 n 代表 0 至 2 的整数，R1 代表氢原子或酰基，R2 代表氢原子、低级烷基或低级烯基，R3 代表低级烷基，R4、R5 和 R6 可以相同或不同，各自代表氢原子或任选取代的烷基，R6 进一步代表甲酰基、羧基、低级烷氧基羰基或低级烷氧基羰基、羧基、低级烷氧基羰基或任选取代的氨基甲酰基，或 R3 和 R4 可结合在一起形成五元环，或 R5 和 R6 可结合在一起形成环烷基，但当 R3 和 R4 形成的五元环与苯环形成苯并呋喃或苯并[b]噻吩时，R6 不存在。
• 4-ALKOXY-2,6-DI-t-BUTYLPHENOL DERIVATIVE
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP0665208B1

  公开（公告）日：1999-01-13